Testicular cancer begins in the testes. Its seriousness depends on the cancer type, size and whether it has spread. The exact diagnosis and extent matter when the specialist team plans care. NHS: testicular cancer definition.
- Seminoma and nonseminoma follow different care pathways; a mixed tumor is managed as nonseminoma. NCI: testicular cancer types.
- Normal tumor markers do not exclude a germ cell cancer. CUH: testicular cancer information.
- Discuss sperm banking before treatment, including the first operation. NHS: testicular cancer treatment.
- Sudden severe testicular pain is an emergency, including possible torsion. NHS: acute testicle pain.
- Supplements should not replace or delay cancer care. NCCIH: cancer and complementary approaches.
Table of contents
- Evidence summary
- What testicular cancer is: germ cell types and other tumors
- Diagnosis and biology: ultrasound, pathology, AFP, beta-hCG and LDH
- Treatment pathways: surgery, surveillance and subtype-specific further care
- Supplements and daily support: nutrition, fatigue and sexual concerns
- What is established and uncertain: markers, screening and prognosis
- Risks and urgent symptoms: torsion, infection and treatment toxicity
- Interactions: medicines, herbs and reproductive precautions
- Who needs extra assessment: fertility, the remaining testis and symptoms
- Clinician-led treatment and follow-up: keep the plan specific
- Animal and laboratory research: proposed mechanisms are not a regimen
- Funding and source roles
- Frequently asked questions
- Sources and funding notes
Evidence summary
Clinical descriptions, care guidance and independently established treatment outcomes have different evidentiary roles. The table identifies what the reviewed sources can support and which financial or clinical questions remain unresolved.
| Question / approach | Evidence reviewed | Funding / conflicts | Interpretation / limits |
|---|---|---|---|
| Types and investigation | High descriptive confidence | Public/provider context; source-chain gaps | Subtype, ultrasound, pathology and markers answer different questions. |
| Treatment pathways | Attributed specialist context | Reviewer ties and supporting trials unclosed | Seminoma/nonseminoma and stage require different plans. |
| Surveillance | Clinical pathway context | Dated institutional sources | Planned follow-up is active care; personal schedule varies. |
| Safety | Urgent precaution context | Clinical pages; contributor gaps | Acute scrotal pain, infection or clot symptoms need prompt care. |
| Supplement efficacy | No independent positive verdict | Dated safety context | No replacement treatment or lab-derived regimen established. |
What testicular cancer is: germ cell types and other tumors
Germ cells normally develop into sperm. The two main cancer groups are seminoma and nonseminoma, which differ in behavior and treatment. Nonseminoma includes several tissue patterns, and a tumor containing both groups follows the nonseminoma pathway. A similar stage label therefore does not mean two people should receive identical care. NCI: testicular cancer types.
A lump, enlargement, change in firmness, heaviness or ache can prompt investigation; some lumps are painless. Back or abdominal symptoms can also occur. These findings have other causes and do not diagnose cancer, but a persistent new change should be examined rather than watched until it becomes painful. NHS: testicular cancer symptoms.
An undescended testicle, previous testicular cancer and a close family history can increase risk. Many people have no clear cause. Risk is not a diagnosis, and a diagnosis does not establish that an injury, sexual activity or a particular food caused it. Discuss relevant childhood surgery and family history. NHS: testicular cancer risk.
Diagnosis and biology: ultrasound, pathology, AFP, beta-hCG and LDH
A clinician examines the testes and may arrange an ultrasound and blood tests. Tissue examined after an operation can confirm the cancer type, while further scans assess extent. Ask which result is still outstanding and who will explain it; the time taken to report a test does not itself determine the diagnosis. NHS: testicular cancer tests.
Ultrasound uses sound waves to produce images without ionizing radiation. It helps investigate a testicular abnormality, but the referring team must interpret and communicate the report alongside the examination and other tests. A scan is part of the pathway rather than an instruction to select treatment independently. CUH: testicular ultrasound.
When a testicular cancer is suspected, removal through a groin incision—inguinal orchiectomy, also spelled orchidectomy—commonly provides diagnostic tissue and removes the primary tumor. Cutting through the scrotum to biopsy the suspected primary is generally inappropriate because it can alter local spread. The surgical route should be planned by an experienced urologist. NCI: testicular cancer diagnosis.
AFP, beta-hCG and lactate dehydrogenase (LDH) inform assessment. Pure seminoma does not produce AFP: a raised AFP requires evaluation for a nonseminomatous component or another explanation, such as liver disease. A single abnormal value should not be interpreted without the pathology and its trend. NCI: professional testicular PDQ.
Treatment pathways: surgery, surveillance and subtype-specific further care
After removal of a stage I tumor, seminoma may be managed with surveillance or selected adjuvant chemotherapy. Nonseminoma may involve surveillance, selected retroperitoneal lymph-node surgery or chemotherapy. In more extensive disease, combination chemotherapy and selected surgery address different situations. These are attributed clinical pathways, not an independently ranked product comparison or a universal regimen. NCI: testicular treatment by stage.
For stage I seminoma, surveillance follows a planned schedule and treats recurrence if it appears. Adjuvant treatment is an alternative to discuss against its immediate and long-term effects. Radiation is no longer a routine preferred option in this setting because of late harms; selected exceptions require specialist discussion. This provider leaflet’s numerical equivalence and relapse claims are not independently adopted. CUH: stage I seminoma options.
Removing one testicle may be the only treatment needed, but additional chemotherapy, radiation or surgery depends on the findings. Ask whether the operation is diagnostic, intended to remove the primary, or directed at disease elsewhere. A prosthetic testicle can be discussed for appearance; it does not make sperm or replace hormonal function. NHS: testicular cancer treatment.
If cancer returns after chemotherapy, the team reassesses prior treatment, current markers, scans and health before choosing salvage care. Further chemotherapy can cause substantial blood-count suppression, infection risk, neuropathy, hearing changes or kidney injury. A previous regimen or another person’s treatment schedule should not be copied for recurrent disease. CUH: relapsed testicular cancer care.
Supplements and daily support: nutrition, fatigue and sexual concerns
Nausea, mouth soreness, changed taste or reduced appetite can make eating difficult during treatment. Report falling intake or weight and ask for dietitian support rather than imposing a restrictive cancer diet. Food and symptom support should fit what the person can manage; they do not establish a way to cure the tumor. NCI: appetite and nutrition.
Fatigue may reflect treatment, anemia, poor sleep, pain or inadequate intake. Describe its timing and effect on ordinary activities so the team can assess contributing problems. Rest and activity need to match current symptoms and function; pushing through significant breathlessness or dizziness should not replace assessment. NCI: cancer fatigue.
Sexual desire, erections, ejaculation and fertility are different issues. Cancer, treatment and distress can affect them in different ways, sometimes beyond treatment. Report changes without assuming that a normal erection proves normal fertility. A sexual-health professional can help with concerns about intimacy, body image or function; a universal assurance of no sexual effects would be misleading. NCI: sexual health during cancer care.
What is established and uncertain: markers, screening and prognosis
Not every germ cell tumor produces measurable blood markers. These tests help with assessment and follow-up, but are not a blanket screening test for all cancers. Rare testicular tumors, including Leydig or Sertoli cell tumors and lymphoma, need their own pathology-based evaluation; this germ cell overview does not supply their complete treatment pathways. CUH: testicular cancer information.
NCI describes no standard routine test for screening people without symptoms. That is different from investigating a new lump or following someone already diagnosed. Finding a change should prompt assessment even without a screening program. Screening claims, self-examination awareness and proof of a mortality benefit should not be treated as interchangeable. NCI: testicular cancer screening.
Staging combines local extent, lymph nodes, distant spread and blood-marker findings, including levels after surgery. A testicular cancer deposit in the lung remains metastatic testicular cancer, not a new primary lung cancer. The exact pathology and marker category matter beyond the stage number; this guide does not turn a population prognosis into an individual prediction. NCI: testicular cancer stages.
A trial may study a new combination, reduced treatment burden or recurrent disease. Eligibility, monitoring, alternatives and sponsorship should be discussed before enrollment. Listing a trial does not prove that its intervention is better or that its finance is independent. No sponsored response or survival estimate is used here as an independent verdict. NCI: clinical trials.
Risks and urgent symptoms: torsion, infection and treatment toxicity
Seek emergency assessment for sudden severe testicular pain, pain with nausea or vomiting, or pain continuing at rest or for more than an hour. Torsion can cut off the testicle’s blood supply and requires rapid care. Do not wait for a cancer referral, try to diagnose it from a lump, or assume that pain rules cancer in or out. NHS: acute testicle pain.
When BEP—bleomycin, etoposide and cisplatin—is prescribed, lung injury from bleomycin is a serious concern. Blood-count suppression, kidney injury, altered hearing and nerve symptoms also require monitoring. Report new breathing or hearing problems promptly. This source describes one local regimen; its doses, cycle count and numerical long-term risks are not generalized to every patient. CUH: BEP treatment safety.
During treatment that weakens infection defenses, fever, chills or feeling suddenly unwell needs urgent contact using the oncology service’s instructions. Keep its emergency number available. Do not wait for the next visit or first hide a possible fever with nonprescription medicine without discussing what to do. NCI: infection during cancer treatment.
Chemotherapy can also increase clot risk. New painful swollen limbs, sudden breathlessness, sharp chest pain or coughing blood require urgent assessment. The team’s emergency pathway takes priority over attributing a symptom to routine side effects. Tell clinicians about problems before the next treatment so monitoring or supportive care can be reviewed. NHS: chemotherapy monitoring and safety.
Interactions: medicines, herbs and reproductive precautions
Give the oncology pharmacist a complete list of prescriptions, nonprescription medicines, concentrated extracts, teas and supplements. St John’s wort is one example of a product that can affect anticancer medicines, but compatibility is drug-specific. A “natural” label cannot establish safety, and a generic internet timing rule cannot make an interaction disappear. NCI: food and supplement interactions.
Lower fertility during treatment does not guarantee that pregnancy is impossible. Ask the team about contraception and any precautions for a partner during and after the actual therapy. The recommended method and duration depend on treatment. Do not use infertility worries as a reason to abandon contraception or invent a fixed waiting period. NCI: male fertility and cancer.
Who needs extra assessment: fertility, the remaining testis and symptoms
Cancer itself may affect semen quality before treatment. Discuss future biological parenthood early and request a fertility specialist before care begins when feasible. The specialists should coordinate any preservation procedure with the oncology timetable; do not independently delay urgent treatment. Sperm banking after puberty differs from experimental preservation of immature testicular tissue. NCI: male fertility and cancer.
A later tumor in the other testicle can be a second primary rather than spread from the first. Particular risk factors may prompt a separate specialist discussion. Removing both testes has consequences for fertility and testosterone; such decisions need explicit counseling. This is not a recommendation for routine biopsy of an unaffected testicle. CUH: the other testicle.
Symptom support can be offered alongside treatment intended to control or cure cancer. Pain, sleep disruption, anxiety and practical difficulties deserve attention even when the oncologic plan is proceeding. Palliative care is not automatically a signal that active treatment must stop; ask for help according to current needs. NCI: palliative care.
Clinician-led treatment and follow-up: keep the plan specific
Surveillance and follow-up can use examination, markers and selected scans to detect change. Their schedule depends on pathology, treatment and circumstances; there is no universal calendar in this guide. Recurrent disease may involve additional chemotherapy, selected surgery or high-dose treatment with stem-cell support in specialist care, rather than routine transplantation for every new diagnosis. NCI: testicular cancer treatment.
Before each chemotherapy treatment, the service reviews symptoms and may check blood counts, body measurements or imaging. Dose and timing decisions belong to that assessment. Ask for a written plan explaining the medicines, supportive care, contact number and reasons to call earlier. Do not change, skip or extend treatment because a public leaflet describes a different course. NHS: chemotherapy monitoring and safety.
Keep the pathology report, marker results and dates, scan reports and treatment summary together. Useful questions include: Is this seminoma, nonseminoma or another tumor? What is the stage and marker category? What is the goal of additional care? Who will organize fertility support? What should happen if a follow-up appointment is missed?
Animal and laboratory research: proposed mechanisms are not a regimen
Cell or animal findings can generate hypotheses, but they do not establish a safe human dose, improved survival or reduced recurrence. Human studies need defined populations, monitoring and meaningful outcomes. A product that affects tumor cells in a dish should not be used as an alternative to an operation, surveillance or prescribed systemic treatment. NCI: research phases.
No supplement cure or replacement for cancer care is established here. Treating a documented deficiency can be appropriate for a separate health reason, with the team’s advice. It does not establish anticancer efficacy. Avoid products that delay diagnosis, complicate medicine safety or promise to prevent recurrence without independent human evidence. NCCIH: cancer and complementary approaches.
Funding and source roles
Research funding at a glance
42 disclosure entries. The counts below summarize independence tiers explicitly assigned in this article. They count disclosures, not studies, funding amounts or evidence quality.
Consult this article’s source and funding notes for named funders, countries, relationships and exceptions where available. Institutional backing, researcher interests and trial sponsorship are separate questions. Public funding alone does not establish independence; commercial ties alone do not prove a claim false. This overview is not a new financial audit.
The source-specific map separates documented institutional funding from disease-page payments and trial sponsorship. Unknown allocations remain unknown. A public agency, charity or academic address does not by itself establish independent treatment efficacy.
| Source | Funding / backers | Country / jurisdiction | Independence | Credibility / incentives / gaps |
|---|---|---|---|---|
| NHS: testicular cancer definition | See the dated national NHS policy below; page, contributor and original-study finance remain unclosed. | England, United Kingdom; national NHS website | Tier 2 — clinical context; provisional | C provisional. Reviewed 2 April 2024. Public-service and institutional incentives; no independently cleared product outcome. |
| NHS: testicular cancer symptoms | See the dated national NHS policy below; page, contributor and original-study finance remain unclosed. | England, United Kingdom; national NHS website | Tier 2 — clinical context; provisional | C provisional. Reviewed 2 April 2024. Public-service and institutional incentives; no independently cleared product outcome. |
| NHS: testicular cancer tests | See the dated national NHS policy below; page, contributor and original-study finance remain unclosed. | England, United Kingdom; national NHS website | Tier 2 — clinical context; provisional | C provisional. Reviewed 2 April 2024. Public-service and institutional incentives; no independently cleared product outcome. |
| NHS: testicular cancer treatment | See the dated national NHS policy below; page, contributor and original-study finance remain unclosed. | England, United Kingdom; national NHS website | Tier 2 — clinical context; provisional | C provisional. Reviewed 2 April 2024. Public-service and institutional incentives; no independently cleared product outcome. |
| NHS: testicular cancer risk | See the dated national NHS policy below; page, contributor and original-study finance remain unclosed. | England, United Kingdom; national NHS website | Tier 2 — clinical context; provisional | C provisional. Reviewed 2 April 2024. Public-service and institutional incentives; no independently cleared product outcome. |
| NHS: acute testicle pain | See the dated national NHS policy below; page, contributor and original-study finance remain unclosed. | England, United Kingdom; national NHS website | Tier 2 — clinical context; provisional | B provisional. Reviewed 26 June 2025. Public-service and institutional incentives; no independently cleared product outcome. |
| NCI: testicular cancer types | See NCI budget, gifts and editorial disclosures below; page, expert and trial allocations remain unclosed. | United States; NCI, Bethesda, Maryland | Tier 2 — clinical context; provisional | C provisional. Updated 17 May 2023. Public-service and institutional incentives; no independently cleared product outcome. |
| NCI: testicular cancer diagnosis | See NCI budget, gifts and editorial disclosures below; page, expert and trial allocations remain unclosed. | United States; NCI, Bethesda, Maryland | Tier 2 — clinical context; provisional | C provisional. Updated 17 May 2023. Public-service and institutional incentives; no independently cleared product outcome. |
| NCI: testicular cancer stages | See NCI budget, gifts and editorial disclosures below; page, expert and trial allocations remain unclosed. | United States; NCI, Bethesda, Maryland | Tier 2 — clinical context; provisional | C provisional. Updated 17 May 2023. Public-service and institutional incentives; no independently cleared product outcome. |
| NCI: testicular cancer screening | See NCI budget, gifts and editorial disclosures below; page, expert and trial allocations remain unclosed. | United States; NCI, Bethesda, Maryland | Tier 2 — clinical context; provisional | C provisional. Updated 8 May 2025. Public-service and institutional incentives; no independently cleared product outcome. |
| NCI: testicular cancer treatment | NCI routes below. Related professional leads have dated ties below; this current page gives no explicit derivation or named reviewer. Exact page payments unknown. | United States; NCI, Bethesda, Maryland | Tier 3 — linked clinical-family provenance; provisional | C provisional. Updated 17 May 2023. Institutional clinical context; direct author/derivation and original-trial chains unclosed. |
| NCI: testicular treatment by stage | NCI routes below. Related professional leads have dated ties below; this current page gives no explicit derivation or named reviewer. Exact page payments unknown. | United States; NCI, Bethesda, Maryland | Tier 3 — linked clinical-family provenance; provisional | C provisional. Updated 17 May 2023. Institutional clinical context; direct author/derivation and original-trial chains unclosed. |
| NCI: professional testicular PDQ | NCI routes below. Leads: Chadha, Chahoud, Gilligan. Dated company relationships documented below; Chadha/current page and underlying-study finances unclosed. | United States; NCI, Bethesda, Maryland | Tier 3 — connected reviewer provenance; clinical context | C provisional. Updated 16 May 2025. PDQ is not a formal guideline; no independently ranked treatment outcome. |
| CUH: testicular cancer information | See CUH’s own accounts below; leaflet allocation, named contributors’ outside interests and trial finance remain unclosed. | United Kingdom; CUH, Hills Road, Cambridge | Tier 2 — clinical context; provisional | C provisional. Approved 14 January 2025, version 6. Public-service and institutional incentives; no independently cleared product outcome. |
| CUH: testicular ultrasound | See CUH’s own accounts below; leaflet allocation, named contributors’ outside interests and trial finance remain unclosed. | United Kingdom; CUH, Hills Road, Cambridge | Tier 2 — clinical context; provisional | C provisional. Approved 7 September 2025, version 2. Public-service and institutional incentives; no independently cleared product outcome. |
| CUH: stage I seminoma options | See CUH’s own accounts below; leaflet allocation, named contributors’ outside interests and trial finance remain unclosed. | United Kingdom; CUH, Hills Road, Cambridge | Tier 2 — clinical context; provisional | C provisional. Approved 5 June 2025, version 6. Public-service and institutional incentives; no independently cleared product outcome. |
| CUH: BEP treatment safety | See CUH’s own accounts below; leaflet allocation, named contributors’ outside interests and trial finance remain unclosed. | United Kingdom; CUH, Hills Road, Cambridge | Tier 2 — clinical context; provisional | C provisional. Approved 24 July 2025, version 7. Public-service and institutional incentives; no independently cleared product outcome. |
| CUH: relapsed testicular cancer care | See CUH’s own accounts below; leaflet allocation, named contributors’ outside interests and trial finance remain unclosed. | United Kingdom; CUH, Hills Road, Cambridge | Tier 2 — clinical context; provisional | C provisional. Approved 1 August 2025, version 5. Public-service and institutional incentives; no independently cleared product outcome. |
| CUH: the other testicle | See CUH’s own accounts below; leaflet allocation, named contributors’ outside interests and trial finance remain unclosed. | United Kingdom; CUH, Hills Road, Cambridge | Tier 2 — clinical context; provisional | C provisional. Approved 13 May 2025, version 6. Public-service and institutional incentives; no independently cleared product outcome. |
| NCI: male fertility and cancer | See NCI budget, gifts and editorial disclosures below; page, expert and trial allocations remain unclosed. | United States; NCI, Bethesda, Maryland | Tier 2 — clinical context; provisional | C provisional. Updated 14 May 2025. Public-service and institutional incentives; no independently cleared product outcome. |
| NCI: sexual health during cancer care | See NCI budget, gifts and editorial disclosures below; page, expert and trial allocations remain unclosed. | United States; NCI, Bethesda, Maryland | Tier 2 — clinical context; provisional | C provisional. Original full body read; date not separately closed. Public-service and institutional incentives; no independently cleared product outcome. |
| NHS: chemotherapy monitoring and safety | See the dated national NHS policy below; page, contributor and original-study finance remain unclosed. | England, United Kingdom; national NHS website | Tier 2 — clinical context; provisional | B provisional. Reviewed 14 February 2025. Public-service and institutional incentives; no independently cleared product outcome. |
| NCI: appetite and nutrition | See NCI budget, gifts and editorial disclosures below; page, expert and trial allocations remain unclosed. | United States; NCI, Bethesda, Maryland | Tier 2 — clinical context; provisional | C provisional. Actual body read; date not separately closed. Public-service and institutional incentives; no independently cleared product outcome. |
| NCI: cancer fatigue | See NCI budget, gifts and editorial disclosures below; page, expert and trial allocations remain unclosed. | United States; NCI, Bethesda, Maryland | Tier 2 — clinical context; provisional | C provisional. Reviewed 20 September 2024. Public-service and institutional incentives; no independently cleared product outcome. |
| NCI: infection during cancer treatment | See NCI budget, gifts and editorial disclosures below; page, expert and trial allocations remain unclosed. | United States; NCI, Bethesda, Maryland | Tier 2 — clinical context; provisional | C provisional. Reviewed 23 January 2020. Public-service and institutional incentives; no independently cleared product outcome. |
| NCI: palliative care | See NCI budget, gifts and editorial disclosures below; page, expert and trial allocations remain unclosed. | United States; NCI, Bethesda, Maryland | Tier 2 — clinical context; provisional | C provisional. Actual body read; date not separately closed. Public-service and institutional incentives; no independently cleared product outcome. |
| NCI: food and supplement interactions | See NCI budget, gifts and editorial disclosures below; page, expert and trial allocations remain unclosed. | United States; NCI, Bethesda, Maryland | Tier 2 — clinical context; provisional | C provisional. Updated 25 April 2024. Public-service and institutional incentives; no independently cleared product outcome. |
| NCI: clinical trials | See NCI budget, gifts and editorial disclosures below; page, expert and trial allocations remain unclosed. | United States; NCI, Bethesda, Maryland | Tier 2 — clinical context; provisional | C provisional. Updated 3 November 2024. Public-service and institutional incentives; no independently cleared product outcome. |
| NCI: research phases | See NCI budget, gifts and editorial disclosures below; page, expert and trial allocations remain unclosed. | United States; NCI, Bethesda, Maryland | Tier 2 — clinical context; provisional | C provisional. Updated 8 November 2024. Public-service and institutional incentives; no independently cleared product outcome. |
| NCI budget | Congressional appropriations through NIH/HHS. The dated page distinguishes enacted funding from requests; it does not allocate money to this disease page. | United States; NCI, Bethesda, Maryland | Tier 3 — institutional financial/process self-report | B provisional. Institutional budget self-report, updated 14 May 2026; statutory scrutiny and an incentive to explain its public mission. |
| NCI Gift Fund and contributions | NCI accepts public donations through its Gift Fund; stamp-related public support is separate. No current disease-page donor ledger or corporate payment is established here. | United States; NCI, Bethesda, Maryland | Tier 3 — institutional financial/process self-report | B provisional. Own contribution information, updated 27 August 2025; fundraising incentives. Donation authority does not prove a named donor funded a page. |
| NCI website editorial process | The website describes expert and editorial review. Its current public budget and gift routes are listed separately; the process page does not supply contributor contracts. | United States; NCI, Bethesda, Maryland | Tier 3 — institutional financial/process self-report | B provisional. Own editorial-process account, reviewed 24 February 2025; institutional credibility incentives. Financial independence of underlying studies remains unknown. |
| PDQ editorial boards and conflicts | NCI provides nongovernment board members honoraria and travel reimbursement. Conflict declarations and recusal are required, but specific board conflicts are not published. | United States; NCI, Bethesda, Maryland | Tier 3 — institutional financial/process self-report | B provisional. Own process disclosure, updated 1 November 2022. Editorial autonomy is distinct from financial independence; current personal and original-trial chains remain incomplete. |
| NHS national website content policy | The dated national policy identifies DHSC funding and states no advertising or corporate sponsorship; it describes staff/contractor declarations. No individual provider finances are established. | England, United Kingdom; national website jurisdiction | Tier 3 — institutional financial/process self-report | B provisional for the dated self-report. Reviewed 14 October 2022; review due 14 October 2025 has passed. Later restructuring, page allocations and source-study ties are not cleared. |
| NCCIH FY2025 congressional justification | NIH/HHS federal budget route. This historical request is not an enacted current budget; the page explicitly says it no longer reflects current HHS policy. Gifts and page allocation remain unclosed. | United States; NCCIH, Bethesda, Maryland | Tier 3 — institutional financial/process self-report | B provisional for historical institutional self-report; budget-advocacy incentives. The proposal cannot establish present appropriations or supplement efficacy. |
| NCCIH: cancer and complementary approaches | See the historical NCCIH fiscal source above; exact education-page allocation, expert interests, and each cited study’s finance are unresolved. | United States; NCCIH, Bethesda, Maryland | Tier 2 — public safety context; provisional | C provisional. Last updated October 2021, distinct from the website footer. Public safety education and institutional incentives; dated synthesis does not independently establish any product outcome. |
| CUH: FY2025–26 audited accounts | NHS commissioning, private/overseas care, research/training, charitable capital and other income; industry/academic partnerships. Leaflet allocations unknown. | United Kingdom; NHS Foundation Trust, Cambridge | Tier 3 — statutory financial self-report | B provisional. Notes 2.1–2.3 and partnership text actually read; service/commercial/budget incentives. |
| Chadha et al.: dated financial declarations | December 2021 article names Moffitt core support, partly NCI P30CA076292. Chadha has no individual declaration listed; JAC’s company ties belong to Jad Chahoud. Current Chadha finances unknown. | United States; then Moffitt, Tampa, Florida | Tier 3 — manuscript financial self-report | B provisional for dated statements, published 10 December 2021. Omission is not proof of no interests; grants do not clear personal contracts. |
| Chahoud: 2026 original author disclosure | Compensated consulting/advisory: AVEO, DAVA, Pfizer, Exelixis, Eisai, Merck. Institutional research: Pfizer, Exelixis, Allogene, Merck, AB Science, Xilio. Article/page allocations and current contract duration unknown. | United States; 2026 author affiliation Orlando Health, Florida; multinational companies | Tier 3 — commercially connected author self-disclosure | B provisional for named declaration, 17 March 2026. PDQ’s older Moffitt affiliation differs; exact employment chronology unclosed. |
| Gilligan: provider financial disclosure | As of 1 April 2024, lists Royal Clinics under threshold-based paid consulting/speaking disclosure. Exact receipts, company ownership/country, current contract and PDQ payments unknown. | United States; Cleveland Clinic, Cleveland, Ohio; Royal Clinics jurisdiction unclosed | Tier 3 — provider financial self-report | B provisional for dated named disclosure. Provider-reputation incentives; direct page now 404, original indexed body read. |
| Gilligan: 2026 original disclosure | Named section links Open Payments physician 844851; specific payment ledger not retrieved. Nearby Lathan/Razis company ties are not attributed to Gilligan. | United States; author Cleveland Clinic; ASCO publisher | Tier 3 — author financial self-disclosure | B provisional for 2026 declaration; precise publication day not separately closed. A registry link is not financial clearance. |
| Cleveland Clinic: 2025/2024 audited accounts | Patient revenue from public/commercial/self-pay routes, research grants, gifts, investments and other income. Exact author/page allocation unclosed. | United States; Ohio nonprofit academic provider | Tier 3 — statutory provider financial self-report | B provisional. Actual 75-page original notes 2–3 personally read in earlier owned myxoma research; service/commercial/budget interests. |
Frequently asked questions
Are seminoma and nonseminoma treated the same? No. They are distinct germ cell groups; mixed seminoma/nonseminoma follows the nonseminoma pathway. NCI: testicular cancer types.
Can tumor markers be normal with testicular cancer? Yes. Not all germ cell tumors produce them; normal results do not exclude a cancer. CUH: testicular cancer information.
Is there a routine testicular cancer screening test? NCI describes no standard routine screening test. A new lump still requires diagnostic assessment. NCI: testicular cancer screening.
Should fertility be discussed before surgery? Yes. Discuss sperm banking before treatment, including the first operation, with the treating team. NHS: testicular cancer treatment.
Should sudden severe testicular pain wait for a cancer appointment? No. It needs emergency assessment, including possible torsion. NHS: acute testicle pain.
Can supplements replace testicular cancer treatment? No replacement is established here. Discuss products and avoid delaying assessment or care. NCCIH: cancer and complementary approaches.
Sources and funding notes
Reviewed 4 October 2026. This adult/adolescent germ cell overview does not close childhood, extragonadal, rare sex-cord/stromal or testicular lymphoma guides. Dates and source roles are retained. Former patient-PDQ URL redirects to a current treatment page without an explicit professional-derivation statement; linked-family reviewer concerns are distinguished from unknown direct page authorship or payment. PDQ clinical context is attributed, with no independently ranked sponsored outcome, personal regimen or survival prediction. Institutional finance is separated from individual contracts and trial allocations. Provider statements of universal sexual safety and numerical risk/equivalence are not adopted.
- NHS: testicular cancer definition — Testis function and individualized disease context.
- NHS: testicular cancer symptoms — New lump, swelling, heaviness and assessment.
- NHS: testicular cancer tests — Ultrasound, tissue diagnosis and staging workup.
- NHS: testicular cancer treatment — Orchidectomy, fertility discussion and selected further care.
- NHS: testicular cancer risk — Undescended testis, personal/family history and uncertain cause.
- NHS: acute testicle pain — Torsion and emergency pain assessment.
- NCI: testicular cancer types — Seminoma, nonseminoma and mixed-tumor distinction.
- NCI: testicular cancer diagnosis — Inguinal tissue diagnosis and marker-based assessment.
- NCI: testicular cancer stages — Stage, post-surgery markers and metastatic identity.
- NCI: testicular cancer screening — No standard routine screening; symptoms require diagnostic care.
- NCI: testicular cancer treatment — Follow-up and selected recurrent-disease care.
- NCI: testicular treatment by stage — Distinct stage I/advanced pathways; no regimen schedule.
- NCI: professional testicular PDQ — AFP interpretation and subtype-specific clinical context.
- CUH: testicular cancer information — Marker limits and rare-histology boundary; broad sexual-function assurances not adopted.
- CUH: testicular ultrasound — Ultrasound process and responsibility for reporting.
- CUH: stage I seminoma options — Surveillance/adjuvant context; numerical equivalence/relapse claims excluded.
- CUH: BEP treatment safety — Bleomycin lung, blood-count, hearing and kidney precautions; no generic cycles.
- CUH: relapsed testicular cancer care — Salvage toxicity and specialist reassessment; outcome claims excluded.
- CUH: the other testicle — Second-primary distinction and bilateral-treatment consequences; numeric risks excluded.
- NCI: male fertility and cancer — Baseline fertility, banking and treatment-specific contraception.
- NCI: sexual health during cancer care — Sexual function differs from fertility; treatment-dependent changes.
- NHS: chemotherapy monitoring and safety — Individual monitoring, infection and clot warnings.
- NCI: appetite and nutrition — Symptoms, intake and dietitian assessment.
- NCI: cancer fatigue — Assessment of contributing problems; no activity prescription.
- NCI: infection during cancer treatment — Dated urgent infection precautions; personal instructions take priority.
- NCI: palliative care — Symptom and practical support alongside treatment.
- NCI: food and supplement interactions — Drug-specific interaction precautions; individual editor/trial finance unclosed.
- NCI: clinical trials — Research participation is not established personal benefit.
- NCI: research phases — Human safety/outcome research versus preclinical signals.
- NCI budget — Institutional finance only; not treatment efficacy or author clearance.
- NCI Gift Fund and contributions — Additional institutional funding route and headquarters; no page allocation inferred.
- NCI website editorial process — Editorial process only; not an efficacy study.
- PDQ editorial boards and conflicts — PDQ process and financial limits; PDQ summaries are not formal clinical guidelines.
- NHS national website content policy — National website funding/editorial policy, not hospital accounts or current author contracts.
- NCCIH FY2025 congressional justification — Dated institutional route only; no current expenditure total or private-gift exclusion.
- NCCIH: cancer and complementary approaches — Dated replacement/delay and supplement-interaction safety context; no independent product efficacy verdict.
- CUH: FY2025–26 audited accounts — Provider revenue only; no contributor or trial clearance.
- Chadha et al.: dated financial declarations — Reviewer provenance only; renal-cancer clinical outcomes excluded.
- Chahoud: 2026 original author disclosure — Named reviewer finance only; penile-cancer treatment claims excluded.
- Gilligan: provider financial disclosure — Dated reviewer relationship only; no inference of specific equity or current fees.
- Gilligan: 2026 original disclosure — Current disclosure-process context only; communication-guideline clinical claims excluded.
- Cleveland Clinic: 2025/2024 audited accounts — Institutional routes only; no named reviewer financial clearance.
Educational research reviewed 4 October 2026. Diagnosis and treatment require a qualified clinician; this article does not provide an individual prescription or replace urgent assessment.
Have a question — or want us to cover something?
Ask about anything on this page, or request the next deep dive: an ingredient, a supplement, or a health concern. We use published research, evidence syntheses, and regulatory guidance, with clear source links.
One daily research roundup
Get the topics, key findings and links from our new articles in one email. At most one digest a day, only when there is something new.